Don't think so...
It's all about pricing...
This stock is undervalued and riks is more than fully priced in.
New floor level is forming and risk apetite will increase share value as we move closer to PII a preliminary results for GBM.
GBM pronostic is very weak.
Primary objective is to get above 20% progression free survival at 6 months.
First cohort of patient should be in the size of 18-20 or so.
First patient got recruited on September 27, 2008 - closed to 9 months ago.
Trial hasn't been interrupted.
All planned centers are operation and recruitement is brisk.
Time is actually on my side.
Management behavior is quite bullish on GBM results.
We will see, who is right.
4601 was customed design for GBM based on Decipher tech (trial and error compound analysis) and design was validated with Caprion Cellcarta technology. I think i am more than ok with compound design.
Also, Management knows what current undisclosed results look like. They opted to for full release of results instead of low ball offer. We will see why they are so bullish.